Add office photos
Employer?
Claim Account for FREE
Piramal Pharma
4.0
based on 1.2k Reviews
Video summary
Company Overview
Company Locations
Working at Piramal Pharma
Company Summary
Piramal Pharma Solutions strives to enhance value for the patients by reducing the burden of disease through early-stage drug discovery and clinical development services.
Overall Rating
4.0/5
based on 1.2k reviews
3% above
industry average
Highly rated for
Company culture, Job security, Work-life balance
Critically rated for
Promotions
Work Policy
Work from office
71% employees reported
Monday to Saturday
45% employees reported
Flexible timing
52% employees reported
No travel
51% employees reported
View detailed work policy
Top Employees Benefits
Health insurance
74 employees reported
Office cab/shuttle
62 employees reported
Job/Soft skill training
61 employees reported
Free meal
50 employees reported
View all benefits
About Piramal Pharma
Founded in2020 (5 yrs old)
India Employee Count1k-5k
Global Employee Count1k-5k
HeadquartersMumbai, Maharashtra, India
Office Locations
Websitepiramalpharma.com
Primary Industry
Other Industries
Are you managing Piramal Pharma's employer brand? To edit company information,
claim this page for free
View in video summary
Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products.
*Includes one facility through minority investment in Yapan Bio
Report error
Managing your company's employer brand?
Claim this Company Page for FREE
Piramal Pharma Ratings
based on 1.2k reviews
Overall Rating
4.0/5
How AmbitionBox ratings work?
5
515
4
349
3
134
2
62
1
93
Category Ratings
3.8
Company culture
3.8
Job security
3.8
Work-life balance
3.7
Salary
3.7
Skill development
3.6
Work satisfaction
3.3
Promotions
Piramal Pharma is rated 4.0 out of 5 stars on AmbitionBox, based on 1.2k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Piramal Pharma
based on 1.1k reviews
3.8
Rated by 109 Women
Rated 3.8 for Work-life balance and 3.8 for Job security
4.0
Rated by 1k Men
Rated 3.9 for Job security and 3.8 for Work-life balance
Work Policy at Piramal Pharma
based on 246 reviews in last 6 months
Work from office
71%
Hybrid
27%
Permanent work from home
2%
Piramal Pharma Reviews
Top mentions in Piramal Pharma Reviews
+ 5 more
Compare Piramal Pharma with Similar Companies
 |  Change Company |  Change Company |  Change Company | |
|---|---|---|---|---|
Overall Rating | 4.0/5 based on 1.2k reviews | 4.1/5 based on 3.3k reviews  | 3.8/5 based on 3.7k reviews | 4.2/5 based on 3.4k reviews |
Highly Rated for | Work-life balance Job security Company culture | Skill development Work-life balance Salary | Job security | Salary Job security Work-life balance |
Critically Rated for | Promotions | Promotions | Promotions |  No critically rated category |
Primary Work Policy | Work from office 71% employees reported | Work from office 54% employees reported | Work from office 88% employees reported | Work from office 76% employees reported |
Rating by Women Employees | 3.8 Good rated by 109 women | 4.0 Good rated by 417 women | 4.0 Good rated by 385 women | 4.0 Good rated by 342 women |
Rating by Men Employees | 4.0 Good rated by 1k men | 4.1 Good rated by 2.7k men | 3.8 Good rated by 3.1k men | 4.2 Good rated by 2.9k men |
Job security | 3.8 Good | 3.8 Good | 4.0 Good | 4.1 Good |
View more
Piramal Pharma Salaries
Piramal Pharma salaries have received with an average score of 3.7 out of 5 by 1.2k employees.
Senior Research Associate
(448 salaries)
Unlock
₹2.4 L/yr - ₹11.4 L/yr
Team Member
(205 salaries)
Unlock
₹1.9 L/yr - ₹5.8 L/yr
Chemist
(159 salaries)
Unlock
₹1.5 L/yr - ₹4.2 L/yr
Research Scientist
(128 salaries)
Unlock
₹5.8 L/yr - ₹14.2 L/yr
Production Chemist
(125 salaries)
Unlock
₹1.4 L/yr - ₹4.2 L/yr
Deputy Manager
(115 salaries)
Unlock
₹5.4 L/yr - ₹14 L/yr
Executive Production
(109 salaries)
Unlock
₹1.9 L/yr - ₹6.6 L/yr
Sales Officer
(91 salaries)
Unlock
₹3.4 L/yr - ₹8 L/yr
Research Associate
(84 salaries)
Unlock
₹2 L/yr - ₹7.5 L/yr
Trainee
(60 salaries)
Unlock
₹1.4 L/yr - ₹3.7 L/yr
Piramal Pharma Interview Questions
A Senior Executive was asked Q. How can you calculate HVAC efficiency?
An Executive was asked 1w agoQ. What is a Zero Liquid Discharge (ZLD) plant?
A QA Executive was asked Q. Which guidelines are followed for process validation?
A Senior Research Associate was asked 1mo agoQ. Describe your project scheme, including retrosynthetic analysis and al...read more
A Production Chemist was asked Q. What is ALCOA?
Piramal Pharma Jobs
Popular Designations Piramal Pharma Hires for
Popular Skills Piramal Pharma Hires for
Current Openings
Piramal Pharma News
View all
Stock Recommendations Today: Defence, IndusInd Bank, Piramal Pharma On Brokerages' Radar
- Jefferies highlighted Defence sector, IndusInd Bank Ltd., and Piramal Pharmaceuticals Ltd. as top companies on brokerages' radar, with a focus on defence indigenisation leading to double-digit revenue growth for Indian defence companies.
- Jefferies added Ambuja Cement Ltd. and Bharat Electronics Ltd. to its model portfolio, while trimming Shriram Finance Ltd. and Coal India Ltd.
- Investec downgraded IndusInd Bank to 'sell', citing potential structural impairment in core operating profitability and uncertainty due to lack of clarity in leadership.
- Morgan Stanley maintained an 'equal-weight' rating for IndusInd Bank, noting significant downside risk to earnings estimates for fiscal 2025–2027.
- Goldman Sachs maintained a 'buy' rating for Piramal Pharma but lowered the target price, expecting recovery in fiscal 2027 with a revenue goal of $2 billion by financial year 2030.
- Jefferies finds current valuations unfavourable for Indian equities, with downside risk to earnings despite supportive capital flows, adding Ambuja Cement and Bharat Electronics to its model portfolio.
- CLSA Price Action suggests bullish trends for Nifty 50, NSE Midcap, and NSE Smallcap indices, with targets and critical support levels outlined for each.
- Morgan Stanley maintained an 'underweight' rating for PB Fintech, anticipating moderating premium growth in fiscal 2026 due to a high base effect.
- CLSA raised the target price for Crompton Consumer and highlighted margin improvement and new business strategies, despite muted growth in the lighting segment.
- Jefferies maintained a 'buy' rating for V-Guard, noting healthy performance and turning debt-free, despite a slight EPS estimate cut for financial year 2026–27.
- NDTV Profit is a subsidiary of AMG Media Networks Limited, an Adani Group Company.
Bloomberg Quint | 16 May, 2025
Buy, Sell Or Hold: Mazagon, Cochin Shipyard, Infosys, Wockhardt, ONGC, Piramal Pharma — Ask Profit
- Analysts discussed the stock prices of various companies including Mazagon Dock Shipbuilders, Cochin Shipyard, Infosys, Wockhardt, ONGC, Piramal Pharma, Bajaj Housing Finance, and Suzlon Energy.
- Mazagon Dock Shipbuilders: Analysts advise holding the stock as it is trading at all-time high levels with positive momentum in defense shares.
- Cochin Shipyard: Analysts recommend holding the stock for its long-term potential despite margin pressures and order-driven nature of the defense business.
- Infosys: Analysts suggest holding the stock for a longer period due to challenges faced by IT companies in growth and technological changes.
- Wockhardt: Analysts provide mixed opinions on buying, selling, or holding the stock, advising to hold for potential upsides in the next two years.
- ONGC: Analyst foresees no significant upmove in the stock due to crude oil price influences and resistance levels.
- Piramal Pharma: Analyst recommends holding the stock for a potential longer-term breakout with targets at previous all-time highs.
- Bajaj Housing Finance: Analyst suggests holding the stock based on positive fourth-quarter performance and asset quality.
- Suzlon Energy: Analyst advises holding the stock as it shows positive momentum and potential resistance breakout for larger trends.
Bloomberg Quint | 15 May, 2025
Buy, Sell Or Hold: NTPC Green Energy, Swiggy, Piramal Pharma, CMS Info — Ask Profit
- Market analysts provide insights on NTPC Green Energy, Swiggy, Piramal Pharma, CMS Info, Power Grid Corporation, and Netweb Technologies
- NTPC Green Energy: Potential for growth due to its large growth footprint and capital infusion from NTPC
- Swiggy: Showing a bearish trend with lower highs and lower lows, may improve if it surpasses Rs 350
- Piramal Pharma: Currently in a consolidation phase with a range of Rs 180 to Rs 240, neutral outlook unless it surpasses Rs 250
- CMS Info Systems: Advised to stay away due to declining cash usage affecting profitability and high valuation
Bloomberg Quint | 3 May, 2025
ICICI Securities revise Nifty 50 target to 27,000 level, Sensex at 90,000
- ICICI Securities has revised the target for Nifty 50 to 27,000 and for Sensex to 90,000.
- The brokerage firm expects corporate earnings to rebound as election-led uncertainty and Union Budget are behind.
- The report highlights that the market provides lucrative opportunities for long-term wealth generation with more reasonable valuations.
- ICICI Securities identifies key sectors for investment and mentions Bank of Baroda, Persistent Systems, Tata Consumer Products, Jindal Steel and Power, Va Tech Wabag, Piramal Pharma, JK Cement, and Titan Company as its top picks.
HinduBusinessLine | 21 Feb, 2025
Glenmark’s US plant to gain amid geopolitical shifts, says CMD
- Glenmark's US plant expected to benefit from geopolitical shifts.
- Cipla and Piramal Pharma also highlight the advantages of having facilities in the US.
- Glenmark optimistic about US market with upcoming product launches.
- In India, Glenmark plans to launch more GLP-1 products for diabetes treatment.
HinduBusinessLine | 17 Feb, 2025
Buy, Sell Or Hold: Swan Energy, Senco Gold, Piramal Pharma, Tata Power, — Ask Profit
- Swan Energy Ltd. - Exit. The company has experienced a significant selloff, reaching multi-year lows.
- Senco Gold Ltd. - Sock witnessed selloff. Further decline to Rs 285-300 levels cannot be ruled out.
- SBI Cards and Payment Services Ltd. - Stay invested. The stock had been an underperformer but has since recovered well and is now outperforming the broader markets.
- Piramal Pharma Ltd. - Stock seen corrective actions. The stock is close to its 200-day moving average and has seen corrective action below this average.
Bloomberg Quint | 14 Feb, 2025
Piramal Pharma Is Jefferies' Top Pick Among Contract Manufacturers With Sector Outlook Positive
- Jefferies sees 2025 as a year of reckoning for Contract Development and Manufacturing Organization (CDMO) stocks.
- Piramal Pharma Ltd. is Jefferies' top pick among contract manufacturers with expectations of margin expansion due to operating leverage.
- CDMO stocks delivered strong returns in 2024, outperforming Nifty and Nifty Pharma, despite mixed earnings.
- Investor confidence in the long-term story of CDMOs has grown, driven by increased optimism and positive management commentary.
Bloomberg Quint | 10 Jan, 2025
Piramal Pharma To M&M: ICICI Securities Shares Top Stock Picks For 2025
- Piramal Pharma Ltd., Mahindra and Mahindra Ltd., KNR Construction Ltd. and Narayana Hrudalaya Ltd. are among ICICI Securities' top stock picks for 2025.
- ICICI Securities expects Nifty 50 to reach the 28,300-mark in 2025, while the target for BSE Sensex is 94,300.
- ICICI Securities predicts a healthy double-digit upside in broader markets in CY25 and projects Nifty earnings to grow at a CAGR of 15% over fiscal 2025-27.
- Investors are advised to focus on companies with growth longevity, healthy balance sheets, and capital-efficient business models, according to ICICI Securities.
Bloomberg Quint | 30 Dec, 2024
Powered by
Compare Piramal Pharma with
Micro Labs
3.6
GlaxoSmithKline Pharmaceuticals
4.1
Novartis
4.1
Biological E
4.2
USV
4.0
Granules India Limited
3.8
Teva Pharmaceuticals
4.0
Sanofi
4.2
Unichem Laboratories
3.8
Fresenius Kabi
4.1
ACG Worldwide
4.0
Novo Nordisk
4.0
Strides Pharma
3.9
Hikal
3.8
Natco Pharma
4.0
Eli Lilly and Company
3.7
Apex Laboratories
3.9
Agilent Technologies
4.1
Merck
4.2
Pfizer Products India
4.0
Edit your company information by claiming this page
Contribute & help others!
You can choose to be anonymous
Companies Similar to Piramal Pharma
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.3k reviews
Micro Labs
Clinical Research, Pharma
3.6
• 2.4k reviews
GlaxoSmithKline Pharmaceuticals
Biotech & Life sciences, Healthcare / Pharma, Manufacturing, Pharma
4.1
• 2k reviews
Novartis
Healthcare, Pharma
4.1
• 1.8k reviews
Biological E
Pharma
4.2
• 1.7k reviews
USV
Manufacturing, Pharma
4.0
• 1.5k reviews
Granules India Limited
Manufacturing, Pharma
3.8
• 1.4k reviews
Teva Pharmaceuticals
Healthcare / Pharma, Clinical Research, Pharma
4.0
• 1.3k reviews
Sanofi
Biotech & Life sciences, Manufacturing, Analytics & KPO, Pharma
4.2
• 1.3k reviews
Unichem Laboratories
Pharma
3.8
• 1.2k reviews
Piramal Pharma FAQs
When was Piramal Pharma founded?
Piramal Pharma was founded in 2020. The company has been operating for 5 years primarily in the Pharma sector.
Where is the Piramal Pharma headquarters located?
Piramal Pharma is headquartered in Mumbai, Maharashtra and has an office in Mumbai.
How many employees does Piramal Pharma have in India?
Piramal Pharma currently has more than 4,600+ employees in India. Research & Development department appears to have the highest employee count in Piramal Pharma based on the number of reviews submitted on AmbitionBox.
Does Piramal Pharma have good work-life balance?
Piramal Pharma has a Work-Life Balance Rating of 3.8 out of 5 based on 1,100+ employee reviews on AmbitionBox. 75% employees rated Piramal Pharma 4 or above, while 25% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Piramal Pharma work-life balance reviews for more details.
Is Piramal Pharma good for career growth?
Career growth at Piramal Pharma is rated as moderate, with a promotions and appraisal rating of 3.3. 25% employees rated Piramal Pharma 3 or below, while 75% employees rated it 4 or above on promotions / appraisal. This rating suggests that while some employees view growth opportunities favorably, there is scope for improvement based on employee feedback. We recommend reading Piramal Pharma promotions / appraisals reviews for more detailed insights.
What are the pros and cons of working in Piramal Pharma?
Working at Piramal Pharma comes with several advantages and disadvantages. It is highly rated for company culture, job security and work life balance. However, it is poorly rated for promotions / appraisal, work satisfaction and skill development, based on 1,100+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Trusted by over 1.5 Crore job seekers to find their right fit company
80 Lakh+
Reviews
10L+
Interviews
4 Crore+
Salaries
1.5 Cr+
Users
Contribute to help millions
AmbitionBox Awards
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2025 Info Edge (India) Ltd.
Follow Us
